Clinical efficacy of metoprolol combined with statins in the treatment of arrhythmia in coronary heart disease
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
万方数据
目的 分析美托洛尔联合他汀类药物治疗冠心病心律失常的临床效果。 方法 随机对照研究。抽取2020年7月至2022年7月济南市第二人民医院收治的冠心病心律失常患者100例，按照随机数字表法分为对照组与观察组，每组50例。对照组给予美托洛尔单药治疗，观察组给予美托洛尔联合他汀类药物治疗。比较两组临床疗效、心功能指标[左心室射血分数(LVEF)、左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)，每分钟输出量(CO)]、血管内皮功能[内皮素－1(ET－1)、血管内皮生长因子(VEGF)，一氧化氮(NO)]、心率变异性[高频功率(HF)、低频功率(LF)，窦性R－R间期标准差(SDNN)]及不良反应发生情况。 结果 观察组总有效率(96.0%，48/50)高于对照组(78.0%，39/50)，差异有统计学意义(P<0.05)。治疗后，两组LVEF、LVEDD、LVESD、CO水平均较治疗前明显改善，且观察组优于对照组(P<0.05)；两组ET－1、VEGF、NO水平均较治疗前明显改善，且观察组优于对照组(P<0.05)；两组HF、LF、SDNN指标均较治疗前升高，且观察组高于对照组(P<0.05)。观察组不良反应发生率(8.0%，4/50)与对照组(6.0%，3/50)比较，差异未见统计学意义(P>0.05)。 结论 美托洛尔联合他汀类药物治疗冠心病心律失常疗效显著，可改善患者的心功能、血管内皮功能，且不良反应少，患者接受度高。 Objective To analyze the effect of metoprolol combined with statins in the treatment of arrhythmia in coronary heart disease. Methods Conducted as a randomized controlled trial, the study included 100 patients with coronary heart disease complicated by arrhythmia admitted to Jinan Second People’s Hospital from July 2020 to July 2022. And they were divided into a control group and an observation group using a random number table method, with 50 cases in each group. The control group was given metoprolol monotherapy, and the observation group was given metoprolol combined with statins therapy. The clinical efficacy, cardiac function indexes, including left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD) and cardiac output (CO), vascular endothelial function assessed by endothelin-1 (ET-1), vascular endothelial growth factor (VEGF) and nitric oxide (NO), heart rate variability assessed by high frequency (HF), low frequency (LF), standard diviation of normal to normal intervals (SDNN), and adverse reactions were compared between the two groups. Results The total effective rate of the observation group (96.0%, 48/50) was higher than that of the control group (78.0%, 39/50), and the difference was significant (P<0.05). After treatment, the levels of LVEF, LVEDD, LVESD, and CO in both groups were significantly improved compared with these indexes before treatment (P<0.05) and the above indicators in the observation group were better than those in the control group after treatment (P<0.05). The levels of ET-1, VEGF and NO in both groups were significantly improved compared with these indexes before treatment, and the above indicators in the observation group were better than those in the control group (P<0.05). After treatment, the HF, LF, and SDNN in both groups increased compared with these indexes before treatment, and the above indicators in the observation group were higher than those in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the observation group (8.0%, 4/50) and the control group (6.0%, 3/50),P>0.05. Conclusions Metoprolol combined with statins has significant therapeutic effects in the treatment of arrhythmia in coronary heart, which can improve cardiac function and vascular endothelial function, with few adverse reactions but high acceptance.
Objective To analyze the effect of metoprolol combined with statins in the treatment of arrhythmia in coronary heart disease. Methods Conducted as a randomized controlled trial, the study included 100 patients with coronary heart disease complicated by arrhythmia admitted to Jinan Second People’s Hospital from July 2020 to July 2022. And they were divided into a control group and an observation group using a random number table method, with 50 cases in each group. The control group was given metoprolol monotherapy, and the observation group was given metoprolol combined with statins therapy. The clinical efficacy, cardiac function indexes, including left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD) and cardiac output (CO), vascular endothelial function assessed by endothelin-1 (ET-1), vascular endothelial growth factor (VEGF) and nitric oxide (NO), heart rate variability assessed by high frequency (HF), low frequency (LF), standard diviation of normal to normal intervals (SDNN), and adverse reactions were compared between the two groups. Results The total effective rate of the observation group (96.0%, 48/50) was higher than that of the control group (78.0%, 39/50), and the difference was significant (P<0.05). After treatment, the levels of LVEF, LVEDD, LVESD, and CO in both groups were significantly improved compared with these indexes before treatment (P<0.05) and the above indicators in the observation group were better than those in the control group after treatment (P<0.05). The levels of ET-1, VEGF and NO in both groups were significantly improved compared with these indexes before treatment, and the above indicators in the observation group were better than those in the control group (P<0.05). After treatment, the HF, LF, and SDNN in both groups increased compared with these indexes before treatment, and the above indicators in the observation group were higher than those in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the observation group (8.0%, 4/50) and the control group (6.0%, 3/50),P>0.05. Conclusions Metoprolol combined with statins has significant therapeutic effects in the treatment of arrhythmia in coronary heart, which can improve cardiac function and vascular endothelial function, with few adverse reactions but high acceptance.
Coronary diseaseArrhythmiaMetoprololStatinsCardiac function
万方数据
